chemotherapy

In a recent study in Blood, the researchers showed that a higher allelic burden after transplantation was associated with higher risk of relapse and mortality.

In a new analysis of the trial, researchers concluded that women over the age of 50 with recurrence scores below 25 appear to see no added benefit from adjuvant chemo.

Agendia, which makes the MammaPrint test, called the report "disappointing" but thinks it still has a shot at landing wider reimbursement in Germany.

The circulating tumor cell-based classifier had an overall accuracy of 89 percent for small-cell lung cancer patients, the researchers reported.

Researchers at the annual meeting of the American Association for Cancer Research discussed their efforts to use genomics to protect patients from radiotherapy toxicity.

The study found that Oncotype DX testing was associated with less frequent chemo use among women at a high clinical risk of recurrence and more frequent chemo in women considered low risk.

The study identified five SNPs significantly associated with five-year progression-free survival and defined risk groups with widely different risks of disease recurrence.

Approximately 85 percent of a 51-member panel at the St. Gallen International Breast Cancer Conference supported the use of Oncotype DX to help decide which patients should receive chemotherapy.

Although the studies presented at the San Antonio Breast Cancer Symposium did not resolve questions about the role of CYP2D6 genotypes or myriad other factors contributing to variability in tamoxifen metabolism, an oncologist at the Mayo Clinic offered some recommendations as to the types of studies that will be necessary to fill knowledge gaps in the field.

Pages

Congress approved a bill Friday that would increase the US National Institutes of Health's funding by $2 billion for fiscal year 2019.

UK's Labour Party calls for a ban on non-invasive prenatal testing for determining sex, BBC News reports.

Sarah Lawrence College's Laura Hercher warns in a New York Times op-ed that more people are going to need help figuring out what their consumer genetic testing results mean.

In PLOS this week: intra-tumor heterogeneity patterns, genomic analysis of Thoroughbred horse origins, and more.